Development of the Drug Product Formulation of the Bevacizumab Biosimilar PF-06439535 (Bevacizumab-bvzr)

ConclusionsResults demonstrated that 20 mM succinate buffer (pH  5.5) is the PF-06439535 preferred formulation, and that sucrose is an effective cryoprotectant for processing and frozen storage, and an effective stabilizing excipient for 5 °C liquid storage of PF-06439535.
Source: Drugs in R&D - Category: Drugs & Pharmacology Source Type: research